Aims & Scope
Journal of Advanced Rheumatology Science (JARS) publishes original research, systematic reviews, and clinical innovations advancing the understanding and treatment of rheumatic and musculoskeletal diseases through immunological, molecular, and therapeutic investigations.
Research Domains
Autoimmune & Inflammatory Rheumatic Diseases
- Rheumatoid arthritis pathogenesis and clinical management
- Systemic lupus erythematosus (SLE) and lupus nephritis
- Spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis)
- Systemic sclerosis (scleroderma) and fibrotic mechanisms
- Vasculitis syndromes (giant cell arteritis, ANCA-associated vasculitis)
- Polymyalgia rheumatica and related inflammatory conditions
Immunology & Molecular Mechanisms
- Immune dysregulation in rheumatic diseases
- Cytokine networks and inflammatory signaling pathways
- Autoantibody profiles and diagnostic biomarkers
- T-cell and B-cell dysfunction in autoimmunity
- Genetic susceptibility and epigenetic modifications
- Complement system activation in rheumatic conditions
Therapeutics & Drug Development
- Biologic agents (TNF inhibitors, IL-6 inhibitors, B-cell depleting therapies)
- Disease-modifying antirheumatic drugs (DMARDs) - conventional and targeted synthetic
- JAK-STAT inhibitors and small molecule therapeutics
- Precision medicine approaches and treatment stratification
- Drug safety, pharmacovigilance, and long-term outcomes
- Combination therapy strategies and treatment optimization
Musculoskeletal Pathology & Bone Metabolism
- Osteoarthritis pathophysiology and cartilage degradation
- Inflammatory arthritis and joint destruction mechanisms
- Bone remodeling in rheumatic diseases
- Osteoporosis and fracture risk in rheumatology patients
- Crystal arthropathies (gout, pseudogout, calcium pyrophosphate deposition)
- Synovial inflammation and pannus formation
Clinical Rheumatology & Patient Care
- Diagnostic imaging (MRI, ultrasound, CT) in rheumatic diseases
- Disease activity indices and outcome measures
- Multidisciplinary management approaches
- Patient-reported outcomes and quality of life
Epidemiology & Public Health
- Disease prevalence, incidence, and geographic variation
- Risk factors and preventive strategies
- Healthcare utilization and economic burden
- Disparities in rheumatologic care access
Pediatric Rheumatology
- Juvenile idiopathic arthritis subtypes
- Childhood-onset systemic lupus erythematosus
- Growth and development in pediatric rheumatic diseases
- Transition of care from pediatric to adult services
Comorbidities & Systemic Manifestations
- Cardiovascular disease in rheumatic conditions
- Interstitial lung disease and pulmonary manifestations
- Renal involvement in systemic autoimmune diseases
- Neuropsychiatric manifestations of rheumatic diseases
Regenerative Medicine
- Stem cell therapy for cartilage regeneration
- Mesenchymal stromal cells in autoimmune diseases
- Tissue engineering approaches for joint repair
Digital Health & AI Applications
- Machine learning for disease prediction and diagnosis
- AI-assisted imaging analysis in rheumatology
- Digital biomarkers and remote monitoring
Microbiome & Environmental Factors
- Gut microbiome dysbiosis in rheumatic diseases
- Environmental triggers of autoimmunity
- Diet and lifestyle interventions
Gene & Cell Therapies
- CAR-T cell therapy for autoimmune diseases
- Gene editing approaches (CRISPR) in rheumatology
- Tolerogenic vaccines and immune modulation
Note: Submissions in Tier 3 areas undergo additional editorial review to ensure strong rheumatologic relevance and methodological rigor.
Article Types & Editorial Priorities
Expedited Consideration
These article types receive priority editorial handling with target first decision within 21 days. Must present original data, rigorous methodology, and significant contribution to rheumatology knowledge.
Regular Consideration
Standard peer review process with target first decision within 35 days. Appropriate for preliminary findings, methodological innovations, or expert perspectives on current topics.
Limited Acceptance
Accepted only if presenting exceptionally rare conditions, novel disease mechanisms, or unique therapeutic insights with broad educational value. Must include comprehensive literature review and mechanistic discussion.
Editorial Standards & Requirements
Reporting Guidelines
All submissions must adhere to internationally recognized reporting standards appropriate to study design:
Research Ethics & Data Policy
- Human Subjects: IRB/Ethics committee approval required. Informed consent documentation. Declaration of Helsinki compliance.
- Data Sharing: Data availability statement mandatory. Raw data deposition in recognized repositories encouraged (Dryad, Figshare, Zenodo).
- Conflicts of Interest: Full disclosure of financial relationships, industry funding, and potential competing interests using ICMJE forms.
- Preprint Policy: Preprint posting permitted (medRxiv, bioRxiv). Must be disclosed at submission. Does not preclude peer review consideration.
- AI & LLM Use: Disclosure required if AI tools used in manuscript preparation. AI cannot be listed as author. Human accountability for content accuracy.
Publication Metrics & Decision Timeline
Article Processing Charges (APC)
JARS operates as a fully open access journal. Authors retain copyright under Creative Commons CC BY 4.0 license. APC information and waiver policies available on the journal website. Fee waivers considered for authors from low-income countries and unfunded research.
Uncertain if your research fits our scope? Contact the editorial office for pre-submission inquiries. We provide guidance within 5 business days to help authors make informed submission decisions.
[email protected]
